<DOC>
	<DOCNO>NCT02386813</DOCNO>
	<brief_summary>This study explore risk factor poor progression-free survival ( PFS ) overall survival ( OS ) ENKTL , establish prognostic model ENKTL patient treat non-anthracycline base treatment .</brief_summary>
	<brief_title>International Extranodal NK/T-cell Lymphoma Project</brief_title>
	<detailed_description>This retrospective cohort study use anonymized information patient ENKTL . The following criterion require : ( 1 ) Patients diagnose ENKTL , nasal type January 1 , 1995 December 31 , 2012 ; ( 2 ) Patients treat non-anthracycline base therapy initial treatment . The pathology initial diagnosis review designated pathologist .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<criteria>Patients diagnose ENKTL , nasal type Patients diagnose January 1 , 1995 December 31 , 2012 Patients treat nonanthracyclinebased therapy initial treatment diagnosis Nonanthracyclinebased therapy include follow treatment : Radiotherapy include concurrent chemoradiation Chemotherapy include anthracycline doxorubicin ( e.g . SMILE , VIPD ) The type salvage treatment criterion exclusion . Thus , patient receive various kind salvage treatment include anthracyclinecontaining regimen include . Patients undergone autologous allogeneic stem cell transplantation also include analysis satisfy abovementioned inclusion criterion . Patients receive anthracyclinebased therapy , CHOP CHOPlike regimens , initial treatment . Patients pathology slide available central review .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>